Disc Medicine Closes Upsized $450M Offering at $75.00; Cash Now $682.8M
IRON has more than doubled off its 52-week low of $40 on light trading volume (0.3× avg).
Summary
Disc Medicine confirmed the closing of its upsized $450 million offering — 6,000,000 shares at $75.00, about $422.4 million net — and disclosed preliminary cash of $682.8 million at September 30, 2026, enough to fund operations into 2030 without product revenue.
Key Events · Financing and Capital Events · IRON
-
Upsized $450M Offering Closes
6,000,000 shares sold at $75.00 per share for $450 million gross; underwriters hold a 30-day option on 900,000 more shares. The offering closed October 22, 2026.
-
Net Proceeds and Runway to 2030
Net proceeds of approximately $422.4 million ($485.9 million if the option is fully exercised) fund operating and capital expenditure plans and debt service into 2030, assuming no bitopertin revenue.
-
Preliminary Cash of $682.8M
Unaudited cash, cash equivalents and marketable securities were approximately $682.8 million as of September 30, 2026, disclosed ahead of the Q3 10-Q and subject to quarter-end close.
-
Underwriting Terms
Jefferies, Leerink, Morgan Stanley and Cantor led as joint book-runners, with LifeSci Capital, BMO and H.C. Wainwright as co-managers; the purchase price to underwriters was $70.50 per share.
Analysis · IRON · Life Sciences
The deal terms have been public for a week, so the offering itself is not new. What is new is the balance sheet: $682.8 million of cash and marketable securities at September 30, 2026, which together with roughly $422.4 million of net proceeds funds operations and debt service into 2030 with no bitopertin revenue assumed. For a company that just reported positive Phase 3 APOLLO data, that removes any near-term financing risk and lets management spend on the EPP/XLP launch build-out. The cost is dilution: 6,000,000 new shares at $75.00, a price below today's $81.74, so buyers of the deal are already sitting on a gain while existing holders absorbed the issuance.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRON was trading at $81.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $40.00 to $99.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.